自体移植后CD19 CAR-T治疗高危复发难治B细胞非霍奇金淋巴瘤
本研究在高剂量化疗联合自体干细胞移植(HDT-ASCT)后给予19-28z CD19 CAR-T细胞,治疗对挽救化疗敏感但高危的复发/难治侵袭性B细胞非霍奇金淋巴瘤。15例受试者中10例出现CAR-T相关神经毒性或细胞因子释放综合征(CRS),2年无进展生存(PFS)为30%(95%CI 20%-70%)。
要点
- HDT-ASCT后输注19-28z CAR-T细胞,15例中10例发生神经毒性或CRS。
- 2年PFS为30%(95%CI 20%-70%),未达主要疗效预期。
- CAR-T细胞中naive样(CD45RA+CCR7+)CD4+和CD8+比例降低与更优PFS相关。
核心结论
- HDT-ASCT后输注19-28z CAR-T细胞与高发生率但可逆的神经毒性和CRS相关。
- HDT-ASCT后效应CD4+和CD8+免疫表型可能改善疾病控制。
研究设计与样本
- 单臂研究,纳入对挽救化疗敏感且高危的复发/难治侵袭性B细胞非霍奇金淋巴瘤患者。
- 患者接受标准HDT-ASCT后,于第+2天和第+3天输注19-28z CAR-T细胞。
- 共15例受试者接受治疗,评估两个剂量水平(5×10^6和1×10^7 19-28z CAR-T细胞/千克)。
主要发现
- 2年PFS为30%(95%CI 20%-70%)。
- CAR-T细胞峰值扩增、存续或细胞因子变化与PFS无关联。
关键数值与推荐
- 剂量限制性毒性在两个剂量水平(5×10^6和1×10^7 19-28z CAR-T细胞/千克)均被观察到。
- 入组条件:对挽救治疗敏感的复发/难治侵袭性B细胞非霍奇金淋巴瘤,且满足PET阳性疾病或骨髓受累。
临床怎么用
- HDT-ASCT后输注19-28z CAR-T细胞需密切监测神经毒性和CRS。
- CAR-T细胞产物中naive样CD4+和CD8+表型比例可能影响PFS,但需进一步验证。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) is the standard of care for relapsed or primary refractory (rel/ref) chemorefractory diffuse large B-cell lymphoma. Only 50% of patients are cured with this approach. We investigated safety and efficacy of CD19-specific chimeric antigen receptor (CAR) T cells administered following HDT-ASCT. Eligibility for this study includes poor-risk rel/ref aggressive B-cell non-Hodgkin lymphoma chemosensitive to salvage therapy with: (1) positron emission tomography-positive disease or (2) bone marrow involvement. Patients underwent standard HDT-ASCT followed by 19-28z CAR T cells on days +2 and +3. Of 15 subjects treated on study, dose-limiting toxicity was observed at both dose levels (5 × 106 and 1 × 107 19-28z CAR T per kilogram). Ten of 15 subjects experienced CAR T-cell-induced neurotoxicity and/or cytokine release syndrome (CRS), which were associated with greater CAR T-cell persistence (P = .05) but not peak CAR T-cell expansion. Serum interferon-γ elevation (P < .001) and possibly interleukin-10 (P = .07) were associated with toxicity. The 2-year progression-free survival (PFS) is 30% (95% confidence interval, 20% to 70%). Subjects given decreased naive-like (CD45RA+CCR7+) CD4+ and CD8+ CAR T cells experienced superior PFS (P = .02 and .04, respectively). There was no association between CAR T-cell peak expansion, persistence, or cytokine changes and PFS. 19-28z CAR T cells following HDT-ASCT were associated with a high incidence of reversible neurotoxicity and CRS. Following HDT-ASCT, effector CD4+ and CD8+ immunophenotypes may improve disease control. This trial was registered at www.clinicaltrials.gov as #NCT01840566.
引用
- Sauter CS, Senechal B, Rivière I, et al. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2019. PMID: 31262783. doi:10.1182/blood.2018883421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。